Skip to content

?The effect of Gossypium hirsutum Extract on Cutaneous leishmaniasis wounds

Evaluation of the Effect of Gossypium hirsutum Extract on Human Cutaneous Leishmaniasis Wound Healing: A Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240713062420N2
Enrollment
80
Registered
2025-06-29
Start date
2025-08-23
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous listeriosis. Cutaneous listeriosis

Interventions

Intervention 1: Intervention group: Standard protocol (local injection of glucantim) plus topical application of cotton extract. Intervention 2: Control group: Standard protocol (local injection of

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65 with confirmed cutaneous leishmaniasis, referred to the city's Leishmaniasis Reference Centers (positive blood smear, eligible for standard topical treatment, and registered in the National Leishmaniasis System), presenting with at least one skin ulcer between 1 and 4 cm.

Exclusion criteria

Exclusion criteria: Systemic treatment criteria include: lesions on sensitive facial areas (eyelids, ears, nose, lips, mouth); five or more lesions; lesion diameter exceeding 3 cm; atypical forms (e.g., sporotrichoid, scarlet fever); lesions on joints; immunocompromising conditions or immunosuppressant use; pregnancy or breastfeeding; pre-existing skin conditions (e.g., eczema, psoriasis, lupus, pemphigus, fungal lesions); mental disorders or severe mental illness (e.g., depression, dementia); facial or ear lesions; lesion infection; or concurrent herbal treatment for the lesion.

Design outcomes

Primary

MeasureTime frame
Wound size reduction (length, width, and area). Timepoint: Every two weeks. Method of measurement: Ruler.

Secondary

MeasureTime frame
Pain, itching, and redness. Timepoint: Before and end of the study. Method of measurement: VAS.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Ghorat

Sabzevar University of Medical Sciences

drghorat@gmail.com+98 21 4401 8717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026